Market Research Logo

Canada Pharmaceutical Industry 2016

Canada Pharmaceutical Industry 2016

After facing some years of stagnation following the economic recession of 2008-2009, the Canadian pharmaceutical industry has been experiencing fluctuating growth since 2012. The industry maintained positive growth in 2014 and had total revenue of over USD 21 billion.

Led by the cardiovascular segment, the Canadian pharmaceutical industry is majorly dominated by foreign-owned multinationals. Over the years, the industry has become more favorable towards generic drugs as compared to its previous preference for branded drugs.

Aruvian Research analyzes the Canadian pharmaceutical industry in its research report – Canada Pharmaceutical Industry. The report is an in-depth analysis of the Canadian Pharmaceutical Industry landscape. The report begins with an introduction to the industry. We analyze the Canadian pharmaceutical industry through an industry definition, a SWOT analysis of the industry, industry statistics, size and structure analysis of the industry, industry growth analysis, market segments, drug sales in the industry, etc. The report also analyzes the industry's competitive landscape, market share of the leading players, major growth drivers in the industry and a profile of how Canada's pharmaceutical industry provides a cost advantage. Clinical trials and market access are other factors that are analyzed in the report.

Moving on to the analysis of OTC Pharmaceuticals in Canada, we analyze the market for OTC pharmaceuticals through an industry overview, industry growth by value, market segmentation, competitive landscape, market share of the major players, analysis of the major industry distribution channels and an industry forecast up to 2019.

The market for generic drugs in Canada is analyzed in a separate section. Generics market is analyzed through an industry overview, industry growth by value and volume both, geographical segmentation of the industry, competitive landscape prevalent in the market and an industry forecast up to 2019.

Regulations impacting the Canadian pharmaceutical industry is analyzed along with industry trends.

A Porter's Five Forces Framework analysis of the Canadian pharmaceutical industry analyzes the bargaining power of buyers and suppliers, competitive rivalry in the industry, the threat of new entrants and the threat of substitutes.

We also analyze the pricing and reimbursement system in the Canadian pharmaceutical industry along with re-import policies for drugs.

Pharmaceutical research and development in Canada is analyzed along with the impact of TRIPS on the Canadian pharmaceutical industry.

A forecast for the Canadian pharmaceutical industry is included till 2019.

Major industry players such as Allergan Plc, AstraZeneca Plc, Apotex Holdings, Sandoz, Johnson & Johnson, and many others are analyzed through a corporate profile, an analysis of their business segments, a financial analysis and a SWOT analysis.

Aruvian’s latest research is a collection of all you need to know about Canada’s Pharmaceutical Industry.


A. Executive Summary
B. Introduction to the Industry
B.1 Industry Definition
B.2 Canada’s Pharmaceutical Sector – SWOT Framework Analysis
B.2.1 Strengths to Build On
B.2.2 Weaknesses to Overcome
B.2.3 Opportunities to Exploit
B.2.4 Threats to Overcome
B.3 Industry Overview
B.4 Size & Structure of the Industry
B.5 Industry Growth by Value Analysis
B.6 Market Segments
B.7 Canadian Drug Sales
B.8 Competition in the Industry
B.9 Market Share Analysis
B.10 Major Growth Factors
B.11 Canada’s Pharmaceutical Industry’s Cost Advantage
B.12 Clinical Trials
B.13 Market Access
C. OTC Pharmaceuticals in Canada
C.1 Industry Definition
C.2 Industry Overview
C.3 Industry Growth by Value Analysis
C.4 Market Segments
C.5 Competition in the Industry
C.6 Market Share
C.7 Distribution Channels
C.8 Industry Forecast
D. Generics Market in Canada
D.1 Industry Definition
D.2 Industry Overview
D.3 Industry Growth by Value Analysis
D.4 Industry Growth by Volume Analysis
D.5 Geographical Segmentation
D.6 Competition in the Industry
D.7 Industry Forecast
E. Regulatory Developments & Trends in the Industry
F. Porter’s Five Forces Strategy Analysis of Canada’s Pharmaceutical Industry
F.1 Bargaining Power of Buyers
F.2 Bargaining Power of Suppliers
F.3 Competitive Rivalry in the Industry
F.4 Threat of New Entrants
F.5 Threat of Substitutes
F.6 Conclusion
G. Pricing and Reimbursement System in the Industry
H. Re-import Policies for Drugs
I. Pharmaceutical R&D in Canada
J. TRIPS & Canada
J.1 Doha Declaration
J.2 Canadian Legislation
J.3 Humanitarian Contributions of Canadian Companies
K. Industry Forecast
L. Major Industry Players
L.1 Allergan Plc
L.1.1 Corporate Profile
L.1.2 Business Segment Analysis
L.1.3 Financial Analysis
L.1.4 SWOT Analysis
L.2 AstraZeneca PLC
L.2.1 Corporate Profile
L.2.2 Business Segment Analysis
L.2.3 Financial Analysis
L.2.4 SWOT Analysis
L.3 GlaxoSmithKline Plc
L.3.1 Corporate Profile
L.3.2 Business Segment Analysis
L.3.3 Financial Analysis
L.3.4 SWOT Analysis
L.4 Johnson & Johnson
L.4.1 Corporate Profile
L.4.2 Business Segment Analysis
L.4.3 Financial Analysis
L.4.4 SWOT Analysis
L.5 Mylan N.V.
L.5.1 Corporate Profile
L.5.2 Business Segment Analysis
L.5.3 Financial Analysis
L.5.4 SWOT Analysis
L.6 Pfizer Inc.
L.6.1 Corporate Profile
L.6.2 Business Segment Analysis
L.6.3 Financial Analysis
L.6.4 SWOT Analysis
L.7 Sanofi SA
L.7.1 Corporate Profile
L.7.2 Business Segment Analysis
L.7.3 Financial Analysis
L.7.4 SWOT Analysis
L.8 Teva Pharmaceutical Industries Limited
L.8.1 Corporate Profile
L.8.2 Business Segment Analysis
L.8.3 Financial Analysis
L.8.4 SWOT Analysis
L.9 Apotex Holdings
L.10 Sandoz International GmbH
M. Glossary of Terms
List of Figures
Figure 1: Average Profit Margins for Selected Industries (2009-2014)
Figure 2: Distribution of Pharmaceutical R&D Expenditures by Geographic Areas - 2014
Figure 3: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014
Figure 4: Share of the Canadian Pharmaceutical Industry in the Americas (%), 2014
Figure 5: Market Share Analysis of the Canadian Pharmaceutical Industry (%), 2014
Figure 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014
Figure 7: Canadian OTC Pharma Market Segmentation (%), 2014
Figure 8: Share of Canada's OTC Market in the Americas (%), 2014
Figure 9: Market Share of the Canadian OTC Pharmaceutical Industry (%), 2014
Figure 10: Leading Distribution Channels in Canada's OTC Pharmaceutical Industry (%), 2014
Figure 11: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019
Figure 12: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014
Figure 13: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014
Figure 14: Share of Canada in the Americas Generics Industry (%), 2014
Figure 15: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019
Figure 16: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019
Figure 17: Porter's Five Forces Analysis of the Canadian Pharmaceutical Industry
Figure 18: Bargaining Power of Buyers in the Canadian Pharmaceutical Industry
Figure 19: Bargaining Power of Suppliers in the Canadian Pharmaceutical Industry
Figure 20: Competitive Rivalry in the Canadian Pharmaceutical Industry
Figure 21: Threat of New Entrants to the Canadian Pharmaceutical Industry
Figure 22: Threat of Substitutes to the Canadian Pharmaceutical Industry
Figure 23: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019
List of Tables
Table 1: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014
Table 2: Canada Pharmaceuticals Market Segmentation % Share, by Value, 2014
Table 3: Share of the Canadian Pharmaceutical Industry in the Americas (in USD Billion & %), 2014
Table 4: Health Expenditure Indicators
Table 5: International Cost Comparison of the Pharmaceutical Industry (US = 100)
Table 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014
Table 7: Canadian OTC Pharma Market Segmentation (in USD Million & %), 2014
Table 8: Share of Canada's OTC Market in the Americas (in USD Million & %), 2014
Table 9: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019
Table 10: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014
Table 11: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014
Table 12: Share of Canada in the Americas Generics Industry (in USD Million & %), 2014
Table 13: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019
Table 14: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019
Table 15: Innovators’ Reasons for Cooperating
Table 16: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019
Table 17: Key Financials of Allergan Plc (in USD Million), 2014-2015
Table 18: Key Financials of AstraZeneca (in USD Million), 2014-2015
Table 19: Key Financials of GSK (in USD Million), 2014-2015
Table 20: Key Financials of Johnson & Johnson (in USD Million), 2014-2015
Table 21: Key Financials of Mylan N.V. (in USD Million), 2014-2015
Table 22: Key Financials of Pfizer Inc. (in USD Million), 2014-2015
Table 23: Key Financials of Sanofi SA (in USD Million), 2014-2015
Table 24: Key Financials of Teva Pharmaceutical Industries (in USD Million), 2014-2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report